CJC-1295: frequently asked questions, answered from the record.

Safety and regulatory status

The questions here are answered from the published record. CJC-1295 is not approved for human use anywhere, and these answers describe what studies measured — not what anyone should do. Two framing facts apply across the whole section: the human evidence base is limited to early pharmacokinetic studies in healthy volunteers ^[1], and the compound is prohibited at all times in sport under WADA Section S2 and banned by bodies such as the NCAA ^[6]. Where an answer cites a general GH-axis effect rather than a CJC-1295 study, it says so.

Is CJC-1295 safe?

CJC-1295 is unapproved for human use and its human safety data are limited to early PK studies ^[1][12]. GH-axis stimulation is associated with fluid retention and effects on insulin sensitivity ^[8][9], and the FDA cited immunogenicity concerns for GH secretagogues including CJC-1295 in 2024 briefing materials. No long-term human safety data exist.

Are CJC-1295 peptides safe?

Human safety data are limited ^[12]. GH-axis stimulation can cause fluid retention and edema and affect insulin sensitivity ^[8][9], and unregulated research-grade material carries purity and identity risks — CJC-1295 has been found as an unlabeled ingredient in seized preparations ^[6]. Not for human use.

Is CJC-1295 FDA approved?

No. CJC-1295 is not approved for human use anywhere; it is handled as a research chemical ^[12]. The 2024 FDA Pharmacy Compounding Advisory Committee reviewed it and did not recommend it for the 503A compounding bulks list. It is also prohibited at all times in sport under WADA Section S2 ^[6].

Is CJC-1295 a steroid?

No. CJC-1295 is a peptide GHRH analog that acts on the pituitary GHRH receptor to release growth hormone ^[1]; it is not an anabolic-androgenic steroid and does not act on androgen receptors. Mechanistically it sits in the GH/IGF-1 axis, a different system from the steroid hormones.

Are peptides safer than TRT?

That comparison is not supported by evidence: CJC-1295 is unapproved and lacks long-term human safety data ^[12], whereas testosterone replacement is an approved therapy with an established profile. No safety ranking can be drawn from the research; the two peptides-versus-TRT categories have not been compared head-to-head.

Side effects and the testosterone questions

The side-effect picture comes mainly from GH-axis physiology, since CJC-1295-specific human data are sparse ^[1][12]. The testosterone questions recur often — they appear in several forms in search data — and the answer is consistent across all of them: CJC-1295 works on the GH/IGF-1 axis, not the hypothalamic-pituitary-gonadal axis, so there is no documented direct effect on testosterone in either direction ^[1][2].

What are the side effects of CJC-1295?

Effects attributable to GH-axis stimulation include fluid retention and edema, driven by GH-stimulated renal sodium reabsorption ^[9], and changes in insulin sensitivity ^[8]. Sustained IGF-1 elevation raises theoretical long-term concerns ^[12]. Human side-effect data specific to CJC-1295 are sparse, because the human record is limited to short PK studies ^[1].

Does CJC affect testosterone?

CJC-1295 acts on the GH/IGF-1 axis, not the hypothalamic-pituitary-gonadal axis ^[1]; the published literature does not show a direct effect of CJC-1295 on testosterone. Its documented readouts are growth hormone and IGF-1, not androgens ^[1][2].

Does CJC-1295 lower testosterone?

There is no evidence in the literature that CJC-1295 lowers testosterone; it works through the GHRH/GH/IGF-1 pathway rather than the gonadal axis ^[1]. No study in the record reports a fall in testosterone.

Does CJC-1295 raise testosterone?

No published data show CJC-1295 raising testosterone; its documented effects are on growth hormone and IGF-1, not on androgen production ^[1][2]. Claims that it boosts testosterone are not supported by the research record.